Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

We think that Thermo Fisher Scientific stock (NYSE: TMO) currently is a better pick compared to Abbott Labs stock (NYSE: ABT), with a similar market capitalization in the healthcare sector, despite its comparatively expensive valuation.

This Healthcare Company Is A Better Pick Over Abbott Stock

GlaxoSmithKline

Merck

Moderna

Pfizer

Vir Biotechnology

Walgreens

President Joe Biden announced during his State of the Union address on Tuesday that individuals who test positive for Covid-19 at a pharmacy will soon be able to get free antiviral treatments immediately after. The cost will be funded by the federal government, which could result in a huge boost to the revenue of companies in the pharmaceutical, pharmacy, and diagnostic industries over the coming year.

Test to Treat Plan can Boost these Stocks

WALTHAM, Mass.--(BUSINESS WIRE)--For the third consecutive year, Thermo Fisher Scientific's pharma and biopharma customers recognized its contract manufacturing leadership in all six categories of the 11th Annual CMO Leadership awards. The annual honors, presented by Life Science Leader and Outsourced Pharma, spotlight excellence in Capabilities, Expertise, Quality, Compatibility, Reliability and Service. The customers evaluated 86 companies across 23 performance metrics. "Patients worldwide ne

Thermo Fisher Scientific Recognized for Contract Manufacturing Leadership

WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher Scientific's PPD clinical research business has been recognized for its robust enterprise learning programs

Thermo Fisher Scientific's PPD Clinical Research Business Earns Honor for Employee Development Driving Customer Success

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at Cowen's 42nd Annual Conference on Monday, March 7, 2022, at 10:30 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving

Thermo Fisher Scientific to Present at Cowen's 42nd Annual Healthcare Conference

SAN JOSE, Calif.--(BUSINESS WIRE)--Thermo Fisher and Symphogen extend an agreement to support biopharmaceutical discovery/development using workflows to improve data confidence.

Thermo Fisher Scientific Continues Collaboration to Support Biopharmaceutical Discovery and Development

We estimate the PPD acquisition to contribute 14% of the company's total revenues in 2022, as well as $25 mln in cost synergies.

Thermo Fisher Scientific: 14% Revenue Boost From PPD Acquisition

Thermo Fisher (TMO) continues to be a trusted partner of Moderna, bringing a wide range of products and services enabling Moderna to deliver innovative medicines at an extraordinary speed and scale.

Thermo Fisher (TMO) Extends Collaboration With Moderna

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific is calling for new proposals for its Oncomine Clinical Research Grant to support research in cancer molecular profiling.

Thermo Fisher Scientific Calls for Grant Proposals to Support Research in Cancer Molecular Profiling

As the pandemic winds down, the market anticipates losing the tailwind from Covid activities, and has punished the entire life science sector. Thermo Fisher was part of this sell-off.

Thermo Fisher: Wrongful Accusation By Market

Thermo Fisher's (TMO) strong pandemic response stance enables it to accelerate its growth strategy, and bump up investments, which encourages it to raise the 2022 core organic growth guidance.

Thermo Fisher (TMO) COVID Test Sales Grow, FX Woes Persist

It's been a tough year so far for Thermo Fisher Scientific Inc (NYSE: TMO), with the stock down nearly 20%, but Jim Lebenthal recommends patience because TMO will get its “mojo” back. Lebenthal backs holding TMO through the sell-off Lebenthal sees the recent sell-off as a period of consolidation, a characteristic of the high-flying stocks.

Expert opinion: ‘Thermo Fisher will get its mojo back'

Moderna Inc. MRNA, -0.53% and life-sciences company Thermo Fisher Scientific Inc. TMO, -1.35% said Wednesday they have entered a long-term agreement to collaborate on large-scale manufacturing of the former's COVID-19 vaccine dubbed Spikevax and other therapies based on its mRNA technology. In a joint statement, the companies said they have already been working together to support Moderna's pipeline with Thermo Fisher providing clinical research and contract manufacturing services, including aseptic fill-finish services and packaging of the COVID vaccine.

Moderna and Thermo Fisher enter long-term agreement on large-scale manufacturing of COVID vaccine

CAMBRIDGE, Mass., & WALTHAM, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna's COVID-19 vaccine, and other investigational mRNA medicines in its pipeline. “Thermo Fisher continues to be a

Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration

WALTHAM, Mass.--(BUSINESS WIRE)--Cell and gene therapy innovators can now leverage new integrated commercial packaging and distribution services from Thermo Fisher Scientific, designed to seamlessly transition therapies from clinic to commercial launch for patients across the U.S. and Europe. The Patheon Commercial Packaging Services for Cell and Gene Therapies (CGT) is an end-to-end solution combining the GMP storage, serialization, ultracold and cryogenic packaging, and global distribution th

Thermo Fisher Scientific Introduces New Cell and Gene Therapy Integrated Commercial Packaging and Distribution Services

Is there still money to be made in Thermo Fisher Scientific Inc. ( TMO , Financial) stock? Analysts think so.

Analysts Think Thermo Fisher Will Continue Its Run

Goldman Sachs

Medtronic

The benchmark S&P 500 index has recovered nearly 5.0% since its low on January 27th. According to Matrix Asset Advisors' David Katz, however, the following three notable names are still on sale.

David Katz: these stocks are a ‘buy' at current levels

WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher Scientific announced a multiyear partnership with Medidata Acorn AI that includes the development of PPD TrueCast

Thermo Fisher Scientific Partners with Medidata Acorn AI to Optimize Clinical Research Site Selection and Speed Patient Enrollment in Clinical Trials

FRANKLIN, Mass.--(BUSINESS WIRE)--Renvo Rapid PCR Test for AerosolSense Sampler

Thermo Fisher Scientific Launches Rapid Environmental PCR Testing Solution That Detects In-Air SARS-CoV-2 Pathogens

Alphabet

While one good quarter doesn't necessarily mean investors should load up on shares of a company, it's definitely a good sign that things are clicking internally. Combine a solid earnings beat with long-term growth trends and a strong financial position and it becomes a lot easier to pull the trigger on a new buy.

3 Stocks with Earnings Beats to Buy Now

Thermo Fisher Scientific (NYSE: TMO) shares are up pre-market after the Q4 2021 results that topped consensus estimates and full-year results. The company posted GAAP diluted earnings per share of $4.17 while adjusted EPS was $6.54.

Thermo Fisher Scientific tops Q4 2021 consensus estimates

Thermo Fisher Scientific's (TMO) CEO Marc Casper on Q4 2021 Results - Earnings Call Transcript

Thermo Fisher Scientific Inc  TMO has posted Q4 revenues of $10.70 billion, up 1% Y/Y, beating the consensus of $9.29 billion. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Thermo Fisher Q4 Earnings Beat Consensus, Clocks COVID-19 Revenue Of $2.45B

Shares of Thermo Fisher Scientific Inc. TMO, +2.24% rallied 2.5% in premarket trading Wednesday, after the analytic and diagnostic instruments company reported big fourth-quarter profit and revenue beats, boosted by nearly $2.5 billion in COVID-19 response revenue. Net income fell to $1.66 billion, or $4.17 a share, from $2.50 billion, or $6.24 a share, in the year-ago period.

Thermo Fisher stock rallies after big earnings beat, boosted by nearly $2.5 billion in COVID-19 response revenue

WALTHAM, Mass., Feb. 2, 2022 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2021.

News for Thermo Fisher Scientific Stock (TMO)